Biotech Values

[DewDiligence]

BMY ZGEN:

My bet is that in another phase-2 [BMY] will run the [BMS650032 + BMS790052] combo + interferon lambda or ribavirin.

For BMY or anyone else to run an HCV trial with a third experimental agent may be too much to expect—at least in the US. It was not that long ago that the FDA forbade trials with only two such agents.